- Home
- SNTI vs CLSD Comparison
SNTI vs CLSD Comparison
Compare SNTI & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CLSD
- Stock Information
- Founded
- SNTI 2016
- CLSD 2011
- Country
- SNTI United States
- CLSD United States
- Employees
- SNTI N/A
- CLSD N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- CLSD Health Care
- Exchange
- SNTI Nasdaq
- CLSD Nasdaq
- Market Cap
- SNTI 85.3M
- CLSD 69.0M
- IPO Year
- SNTI N/A
- CLSD 2016
- Fundamental
- Price
- SNTI $3.56
- CLSD $0.78
- Analyst Decision
- SNTI Strong Buy
- CLSD Strong Buy
- Analyst Count
- SNTI 1
- CLSD 5
- Target Price
- SNTI $12.00
- CLSD $4.80
- AVG Volume (30 Days)
- SNTI 25.9K
- CLSD 176.1K
- Earning Date
- SNTI 05-06-2025
- CLSD 05-14-2025
- Dividend Yield
- SNTI N/A
- CLSD N/A
- EPS Growth
- SNTI N/A
- CLSD N/A
- EPS
- SNTI N/A
- CLSD N/A
- Revenue
- SNTI N/A
- CLSD $3,764,000.00
- Revenue This Year
- SNTI N/A
- CLSD N/A
- Revenue Next Year
- SNTI N/A
- CLSD $476.77
- P/E Ratio
- SNTI N/A
- CLSD N/A
- Revenue Growth
- SNTI N/A
- CLSD N/A
- 52 Week Low
- SNTI $1.52
- CLSD $0.70
- 52 Week High
- SNTI $16.94
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- SNTI 58.08
- CLSD 40.82
- Support Level
- SNTI $3.04
- CLSD $0.77
- Resistance Level
- SNTI $3.25
- CLSD $0.79
- Average True Range (ATR)
- SNTI 0.23
- CLSD 0.05
- MACD
- SNTI 0.04
- CLSD -0.01
- Stochastic Oscillator
- SNTI 89.83
- CLSD 25.14
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.